Clinical data indicate that tamoxifen resistant breast cancers often have an increased expression of the receptor tyrosine kinase (RTK) epidermal growth factor (EGF) receptor (EGFR/ERBB1) and its family member ERBB2 [1,4,5]. This evidence concerns the gene EGFR and breast carcinoma.